|
| Gene | Human tumors | Animal model | Treatment | Induced phenotype | Spontaneous phenotype |
|
FHIT*
3p14.2
Deletions
translocations | Head and Neck, Lung, Larynx, Liver, Pancreas, Digestive Tract, Urinary Tract, Prostate, Spleen, Bone Marrow | FHIT KO | Radiation | Increased multiorgan tumor involvement respect WT, but equal tumorigenesis | |
| | FHIT KO | B(a)P
(Benzo(a)pyrene) | KO and WT mice were equally sensitive; FHIT+/− mice showed uterine preneoplasias | |
| | FHIT KO | ECS (Environmental cigarette smoke) | After exposure, FHIT loss was observed also in WT mice. WT and FHIT+/− mice did not show significant differences | |
| | FHIT KO | BBN (N-butyl-N-hydroxybutyl) nitrosamine) | 28% of FHIT−/− and 46% of FHIT+/− versus 8% of WT mice developed bladder invasive carcinomas | |
| | FHIT KO X Vhl KO | | | Lung adenocarcinomas
in 44% |
| | FHIT KO X Vhl KO | DMN (Dimethyl-nitrosamine) | Lung adenocarcinomas in 100% | |
| | FHIT+/− X HER2/neu (mammary tumor promoter) | | | Mammary tumors
in 100% |
| | FHIT KO X Nit KO | NMBA (N-nitroso-methyl-benzylamine) | ~100% more gastric tumors than FHIT−/− alone | |
|
WWOX
16q23.2
Deletions
translocations | Lung, Digestive Tract, Liver, Pancreas, Breast, Ovarian, Prostate, CNS, Urinary Tract, Bone, Thyroid, Bone Marrow | Wwox KO | | | Postnatal lethality for −/− mice.
Surviving mice showed metabolic disorders and developed femoral focal lesions resembling to osteosarcoma. +/− mice showed higher incidence of lung and mammary tumors than WT mice |
| | | | | |
| | | ENU (Ethyl-Nitroso- Urea) | 80% of +/− mice developed lymphoblastic leukemia, lung, mammary, and liver tumors | |
| | | NMBA (N-nitroso-methyl-benzylamine) | ~100% of +/− mice with forestomach tumors | |
| | Wwox Hypomorphic strain (very low expression of Wwox) | | | Short lifespan. Females exhibited high incidence
of lymphomas |
|
PARK2
6q26
Deletions
translocations | Ovary, breast, esophagus, liver, colon, lung, renal, CNS, hematopoietic | Park2 KO | | | Motor and cognitive defects |
| | Park2 X Apc | | | 4-fold increase in adenomas than control mice; all stages neoplastic lesions |
|
CAV-1
7q31.2
Deletions
translocations | Downregulated in: ovarian, lung, mammary tumors
Upregulated in: prostate, bladder, thyroid, esophageal carcinomas | Cav-1 KO | | | Normal. Reduction of
Cav-2 expression |
| | Cav-1 KO | DMBA (7,12-dimethyl
benzanthracene) | Development of epidermally derived tumors | |
| | Cav-1 X MMTV-PyMT | | | Acceleration of the development of mammary lesions |
| | Cav-1 X Tramp | | | Decreased incidence in prostate tumors and loco-regional and distal metastasis |
|
TES
7q31.2
Deletions
translocations | Head and Neck, gastric, breast, hematopoietic, prostate, CNS | Tes KO | | | Normal |
| | Tes Ko | NMBA(N-nitroso-methyl-benzylamine) | | High incidence of forestomach tumors |
|
